Sydney, Australia – 14 June 2024 – LTR Pharma, an ASX-listed company dedicated to improving men's health, is proud to announce be announced as the winner of the prestigious IPO of the Year Award. This accolade highlights the company's remarkable entry into the public market and its promising future in the healthcare sector. The Australian Stockbrokers Foundation award ceremony was held last night at the Sofitel Wentworth in Sydney and celebrated LTR Pharma's innovation and impact.
Alpine Capital has been instrumental in this achievement, acting as the Lead Manager for LTR Pharma's successful IPO. Their expertise and strategic guidance have played a crucial role in navigating the complexities of the public listing process and positioning LTR Pharma for ongoing success.
Since IPO, LTR Pharma stock has traded up 300% above its listing price of 20c following the announcement of the announcement of the exceptional initial SPONTAN results, with full trial results anticipated in the coming months.
LTR Pharma's primary focus is on enhancing men's physical and mental health through the commercialisation of their groundbreaking nasal spray treatment for Erectile Dysfunction (ED). ED is a significant health issue affecting millions of men worldwide, often leading to diminished self-esteem and strained relationships. LTR Pharma's lead product, SPONTAN, offers a unique solution with its innovative mechanism of action.
SPONTAN distinguishes itself from existing ED therapies through its intranasal delivery technology of a PDE5 inhibitor. The nasal cavity, being a highly vascular part of the body, facilitates rapid and even absorption of the drug, allowing it to take effect within 10 minutes or less. This swift action empowers men to regain control over the timing, spontaneity, and enjoyment of their sexual experiences, making SPONTAN a revolutionary advancement in ED treatment.
Phil Cawood, co-founder of Alpine Capital, expressed his enthusiasm: "Working with LTR Pharma on their IPO has been a rewarding experience. Their commitment to innovation in men's health is truly inspiring, and we are proud to have played a role in their successful market entry. This recognition is well-deserved, and we anticipate a bright future for the Company."
Contact details:
For further information
Jane Morgan
